Get started
Author

Cara Solimeno

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
2018 · M. Diossy, L. Reiniger, et al. · Annals of Oncology · 88
PDF
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
2015 · Virginia G. Kaklamani, Jacqueline S. Jeruss, et al. · Breast Cancer Research and Treatment · 75
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
2018 · Jai N. Patel, Ioana Braicu, et al. · British Journal of Cancer · 70
PDF
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
2021 · Jeffrey A. How, Amir A. Jazaeri, et al. · Cancers · 59
PDF
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort
2022 · Carsten Denkert, Marcel Romey, et al. · Journal of Molecular Diagnostics · 43
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
2023 · Lauren Lenz, Chris Neff, et al. · Breast Cancer Research and Treatment · 13
PDF
Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients
2024 · Olivier Cussenot, Kirsten M. Timms, et al. · European Urology Oncology · 6
PDF
Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score
2015 · Yan Wang, Stefano Cairo, et al. · Cancer Research · 6
The molecular landscape of genome instability in prostate cancer (PC)
2016 · K. Timms, J. Cuzick, et al. · Annals of Oncology · 5
PDF
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579).
2015 · Virginia G. Kaklamani, Elisha Hughes, et al. · Journal of Clinical Oncology · 4
Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)
2016 · J. Patel, J. Sehouli, et al. · Annals of Oncology · 3
PDF
Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).
2015 · Jai Narendra Patel, Jahid Sehouli, et al. · Journal of Clinical Oncology · 3
Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
2019 · M. Diossy, L. Reiniger, et al. · Annals of Oncology · 2
PDF
2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)
2022 · Carsten Denkert, Marcel Romey, et al. · International Journal of Gynecological Cancer
PDF
Abstract P5-13-09: Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes
2022 · Kirsten M Timms, Lauren Lenz, et al. · Cancer Research
Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313
2019 · P Sharma, WB Barlow, et al. · Cancer Research
Works count: 16
Citation count: 376
H-index: 6
I10-index: 6
Year
Topic
Type